Signaling pathways
-
BA2872 PTC-028Summary: PTC-028 is an orally effective inhibitor of stem cell factor for the study of ovarian cancer. - BA2873 LuxeptinibSummary: Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, potent inhibitor.
- BA2874 NHWD-870Summary: NHWD-870 is a potent, orally active and selective inhibitor.
- BA2875 BETd-260Summary: BETd-260 (ZBC260), a PROTAC linked by ligand and ligand-conjugated, was able to reduce protein activity at a low concentration of 30 pM in leukemia cells RS4;11.
- BA2877 SKI-178Summary: SKI-178 is a potent sphingosine kinase-1 and inhibitor.
- BA2878 DanvatirsenSummary: Danvantisen is a targeted antisense oligonucleotide with potential antitumor activity.
- BA2879 UBX1325Summary: UBX1325 is an inhibitor that promotes apoptosis in senescent cells.
- BA2880 KinsenosideSummary: Kinsenoside is the main active ingredient isolated from the genus Cleomiscus and possesses a wide range of biological activities and pharmacological effects.
- BA2881 AG-825Summary: AG-825 is a selective, ATP-competitive, inhibitor of tyrosine phosphorylation.
- BA2883 S130Summary: S130 is a high affinity, selective inhibitor of cysteine proteases with a value of 3.24 μM.